Fasoracetam - Aevi Genomic Medicine

Drug Profile

Fasoracetam - Aevi Genomic Medicine

Alternative Names: AEVI-001; Fasoracetam; LAM 105; MDGN-001; NFC 1; NS 105

Latest Information Update: 16 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nippon Shinyaku
  • Developer Aevi Genomic Medicine
  • Class Neuroprotectants; Nootropics; Piperidines; Small molecules
  • Mechanism of Action Cholinergic receptor agonists; GABA B receptor antagonists; Metabotropic glutamate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Attention-deficit hyperactivity disorder
  • Phase II Di George syndrome
  • Phase I Autistic disorder
  • Discontinued Cognition disorders; Major depressive disorder

Most Recent Events

  • 15 Oct 2018 Aevi Genomic Medicine completes enrolment in the phase II ASCEND trial for Attention Deficit Hyperactivity Disorder
  • 15 Oct 2018 Aevi Genomic Medicine plans a phase III trial
  • 17 Aug 2018 Aevi Genomic initiates enrolment in a phase II trial for Attention-deficit hyperactivity disorder (In children, In adolescents) in USA (PO) (NCT03609619)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top